2-thioxo-3,5,5-trimethylthiazolidin-4-one | 10574-71-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 2-thioxo-3,5,5-trimethylthiazolidin-4-one
• 英文别名: 3,5,5-Trimethylthiazolidin-4-one-2-thione；3,5,5-trimethyl-2-thioxo-thiazolidin-4-one；3,5,5-Trimethyl-2-thioxo-thiazolidin-4-on；3,5,5-Trimethyl-2-sulfanylidene-1,3-thiazolidin-4-one
• CAS: 10574-71-7
• 化学式: C₆H₉NOS₂
• 分子量: 175.276
• InChiKey: HXAIJRJXPQZSQL-UHFFFAOYSA-N

物化性质

• 熔点：
  90-92 °C
• 沸点：
  222.3±23.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  77.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-(3,4-二氯苯基)-1-羟基-1-(3,5,5-三甲基-2-硫代噻唑烷-4-基)脲 在 盐酸 、 三乙胺 、 氯甲酸甲酯 作用下， 以 乙醇 、 水 为溶剂， 生成 2-thioxo-3,5,5-trimethylthiazolidin-4-one
  参考文献：
  名称：

  Reaction of carbamoyl derivatives of 4- and 5-hydroxyl-aminothiazolidine-2-thiones and 4-hydroxylaminoimid-azolidin-2-one with methyl chloroformate. Properties of substituted 1,2,4-oxadiazolidine-3,5-diones

  摘要：

  DOI：

  10.1007/bf00509717

文献信息

• [EN] METABOLICALLY-ACTIVATED DRUG CONJUGATES TO OVERCOME RESISTANCE IN CANCER THERAPY<br/>[FR] CONJUGUÉS DE MÉDICAMENTS ACTIVÉS MÉTABOLIQUEMENT POUR VAINCRE LA RÉSISTANCE DANS UNE THÉRAPIE DU CANCER
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2015149001A1

  公开（公告）日：2015-10-01

  Described are combination therapies and metabolically-activated drug conjugates and their use in treating cancer in subjects.

  本文描述了联合治疗和代谢激活药物结合物及其在治疗受试者的癌症中的应用。
• Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
  申请人：Poniard Pharmaceuticals, Inc.

  公开号：EP1980246A1

  公开（公告）日：2008-10-15

  Use is provided of a compound of formula (I): wherein Z is C=O or a covalent bond; Y is H or O(C1-C4)alkyl, R1 and R2 are individually (C1-C4)alkyl or together with N are a saturated heterocyclic group, R3 is ethyl or chloroethyl, R4 is H or together with R3 is -CH2-CH2- or -S-, R5 is O(C1-C4)alkyl or H and R6 is O(C1-C4)alkyl or H with the proviso that when R4, R5, and R6 are H, R3 is not ethyl; or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in: the treatment or prevention of cardiovascular pathologies e.g. atherosclerosis, thrombosis, myocardial infarction or stroke, inhibiting smooth muscle cell (SMC) proliferation associated with procedural vascular trauma, preventing or treating a cardiovascular or vascular indication in a mammal characterised by a decreased lumen diameter, or increasing the level of TGF-beta in a mammal, effective to elevate the level of TGF-beta to treat and/or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke. Useful compounds include idoxifene, toremifene or salts thereof. Further provided is a method for identifying an agent that elevates the level of TGF beta. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro. Also provided is a therapeutic method comprising inhibiting smooth muscle cell proliferation associated with procedural vascular trauma employing the administration of tamoxifen or structural analogs thereof, including compounds of formula (1).

  提供了式 (I) 化合物的用途： 其中 Z 是 C=O 或共价键； Y 是 H 或 O（C1-C4）烷基、 R1 和 R2 单独为 (C1-C4) 烷基或与 N 一起为饱和杂环基团、 R3 是乙基或氯乙基、 R4 是 H 或与 R3 一起是-CH2-CH2-或-S-，R5 是 O（C1-C4）烷基或 H，R6 是 O（C1-C4）烷基或 H，但当 R4、R5 和 R6 是 H 时，R3 不是乙基； 或其药学上可接受的盐，用于制造以下用途的药物治疗或预防心血管病变，如动脉粥样硬化、血栓形成、心肌梗塞或中风；抑制与程序性血管创伤相关的平滑肌细胞（SMC）增殖；预防或治疗哺乳动物以管腔直径减小为特征的心血管或血管适应症；或提高哺乳动物体内 TGF-beta 的水平，有效提高 TGF-beta 的水平以治疗和/或预防动脉粥样硬化、血栓形成、心肌梗塞和中风等疾病。有用的化合物包括依多昔芬、托瑞米芬或其盐类。本发明还提供了一种鉴定可提高 TGF beta 水平的制剂的方法。本发明的另一个实施方案是一种测定体外 TGF-beta 的检测方法或试剂盒。本发明还提供了一种治疗方法，包括通过施用他莫昔芬或其结构类似物（包括式（1）化合物）来抑制与程序性血管创伤相关的平滑肌细胞增殖。
• ANTI-CD27 ANTIBODY
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2314628A1

  公开（公告）日：2011-04-27

  The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically recognizes a polypeptide encoded by CD27 gene containing an O-linked sugar chain to which galactose is not bound, and binds to its extracellular region; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.

  本发明提供了一种单克隆抗体，它能特异性识别含有未与半乳糖结合的 O 型糖链的 CD27，并与其细胞外区域结合，或提供了一种使用该单克隆抗体的方法。本发明可提供一种单克隆抗体或其抗体片段，它能特异性识别 CD27 基因编码的多肽，该多肽含有未与半乳糖结合的 O 型糖链，并能与其细胞外区域结合；一种产生该抗体的杂交瘤；一种编码该抗体的 DNA；包含该 DNA 的载体；可通过转化该载体获得的转化体；使用该杂交瘤或转化体生产抗体或其抗体片段的工艺；以及包含该抗体或其抗体片段作为活性成分的诊断剂或治疗剂。
• ANTIBODY RECOGNIZING TURN STRUCTURE IN AMYLOID ß
  申请人：Kyoto University

  公开号：EP2489675A1

  公开（公告）日：2012-08-22

  Provided is a therapeutic method exclusively targeting an amyloid β protein (Aβ) having a specific turn structure of Aβ. Specifically provided is an antibody which specifically recognizes an amyloid β having a turn structure at amino acids positions 22 and 23. Also provided are a medicinal composition comprising, as the active ingredient, an antibody specifically recognizing a toxic conformer of amyloid β, an assay kit for a toxic conformer of amyloid β, a diagnostic for Alzheimer's disease, etc.

  本发明提供了一种专门针对具有特定淀粉样β转折结构的淀粉样β蛋白（Aβ）的治疗方法。具体而言，本发明提供了一种抗体，该抗体可特异性识别在氨基酸位置 22 和 23 处具有转折结构的淀粉样蛋白 β。此外，还提供了一种药物组合物，其活性成分包括特异性识别淀粉样蛋白 β 的毒性构象的抗体、淀粉样蛋白 β 的毒性构象的检测试剂盒、阿尔茨海默病的诊断方法等。
• ANTI-IGA1 ANTIBODY
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2520648A1

  公开（公告）日：2012-11-07

  An object of the present invention is to provide a monoclonal antibody which is effective for diagnosing IgA nephropathy and specifically recognizes and binds to a hinge region of a polypeptide encoded by a heavy chain gene of immunoglobulin A1 that comprises a serine/threonine-linked sugar chain to which galactose is not bound. According to the present invention, it is possible to provide a monoclonal antibody or an antibody fragment thereof that specifically recognizes and binds to a hinge region of a polypeptide encoded by a heavy chain gene of immunoglobulin A1 that comprises a serine/threonine-linked sugar chain to which galactose is not bound, to provide a diagnostic agent using the antibody or the antibody fragment thereof, and to provide a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.

  本发明的目的是提供一种单克隆抗体，它能有效诊断 IgA 肾病，并能特异性地识别和结合由免疫球蛋白 A1 的重链基因编码的多肽的铰链区，该多肽包括丝氨酸/苏氨酸连接的糖链，其中半乳糖未被结合。根据本发明，可以提供一种单克隆抗体或其抗体片段，该抗体或其抗体片段能特异性地识别并结合由免疫球蛋白 A1 重链基因编码的多肽的铰链区，该多肽包括丝氨酸/苏氨酸连接的糖链，半乳糖不与之结合；提供一种使用该抗体或其抗体片段的诊断药剂；以及提供一种包含该抗体或其抗体片段作为活性成分的治疗药剂。